Balance Therapeutics, spun out of Stanford, is a R&D company focused on developing therapeutics to address conditions of intellectual disability to include Down syndrome and Alzheimers disease. The firm's pharmacological approach is based on technology licensed from Stanford University that has demonstrated promising potential to address cognitive deficits in animal models of Down syndrome and Alzheimers disease. Focused on the development of BTD-001 DS102, a placebo-controlled molecule product that can be administered orally for young adults and adolescents with Down syndrome, clinical trials are currently in progress for Down Syndrome. The firm has a wholly owned subsidiary in Melbourne, Australia.
